- « Previous Releases | Next Releases »
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the appointment of Mr. Thomas R. Staab, IIas BioCryst's new Chief Financial Officer, effective July 1, 2011, and that Mr. Stuart R. Grant, BioCryst's current CFO, has agreed to extend his employment with the Company an additional month to June 30, 2011.
"On behalf of BioCryst's employees and Board of Directors, I wish to thank
Stuart Grantfor his four years of dedicated leadership, unwavering financial discipline and his commitment to a smooth transition of the financial reins of the company," said Jon P. Stonehouse, President and Chief Executive Officer, BioCryst Pharmaceuticals. "Tom Staab brings nearly twenty years of finance and biotech accomplishments to BioCryst. We expect his experience and reputation in the industry to enable us to sustain our solid financial footing and to help us achieve our goal of building an enduring, successful biopharmaceutical company." Mr. Staabis a highly qualified pharmaceutical executive who over the last decade has served as Chief Financial and Accounting Officer of two growing NASDAQ-listed companies. He brings strong skills and experience in the financial stewardship of publically-traded companies, development and commercialization of pharmaceutical products and raising funds through strategic partnerships, equity and debt financings.
Mr. Staabserved as Executive Vice President, CFO and Treasurer of Inspire Pharmaceuticals from May 2003through its $430 millionacquisition by Merck & Co., Inc. in May 2011. Prior to joining Inspire, he held senior financial positions of Acting CFO and Treasurer at Triangle Pharmaceuticals, Inc., through its $465 millionacquisition by Gilead Sciences, Inc. in 2003. Before joining Triangle, Mr. Staabspent eight years working for PricewaterhouseCoopers LLPproviding audit and business advisory services to national and multi-national corporations in the biotechnology, pharmaceutical, pulp and paper and communications industries. Tom currently serves on the Board of the North Carolina Biosciences Organizationand is a member of its Audit Committee, and he has been received awards for his contribution and leadership to other organizations. He is a Certified Public Accountant and received a B.S. in Business Administration and a Masters of Accounting from the University of North Carolina at Chapel Hill.
"I am excited about the opportunity to work with the entire BioCryst team and to continue to build the company towards sustainability," said
Mr. Staab. "I feel privileged to be given the opportunity to join BioCryst at such an exciting stage in its corporate development."
BioCryst Pharmaceuticals BioCryst Pharmaceuticalsdesigns, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, inflammatory diseases and cancer. BioCryst currently has three novel late-stage compounds in development: peramivir, a neuraminidase inhibitor for the treatment of influenza, BCX4208, a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of gout, and forodesine, an orally-available PNP inhibitor for hematological malignancies. Utilizing crystallography and structure-based drug design, BioCryst continues to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. For more information, please visit the Company's website at www.biocryst.com.
This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the
SECand located at http://investor.shareholder.com/biocryst/sec.cfm.
BioCryst Pharmaceuticals Robert Bennett, 919-859-7910
BioCryst Pharmaceuticals, Inc.
News Provided by Acquire Media